Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs
Authors:
- D J EastmanDED J Eastman
- A LimALA Lim
- C LucasCLC Lucas
- M PetersonMPM Peterson
- J VennariJVJ Vennari
- R P WeissburgRWR P Weissburg
- T WrinTWT Wrin
- C R KensilCKC R Kensil
- M J NewmanMNM J Newman
- 1 February 1995
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 11 (2) , 203-209
Abstract
The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of the immune response to recombinant gp120 in humans and chimpanzeesAIDS, 1994
- Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse IsolatesAIDS Research and Human Retroviruses, 1992
- The Control of the Antibody Isotype Response to Recombinant Human Immunodeficiency Virus gp120 Antigen by AdjuvantsAIDS Research and Human Retroviruses, 1992
- Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibodyNature, 1992
- Studies on the immunogenicity of chinese hamster ovary cell-derived recombinant gp120 (HIV-1IIIB)Vaccine, 1991
- Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing DeterminantScience, 1990
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptorCell, 1987
- Genetic variability of the AIDS virus: Nucleotide sequence analysis of two isolates from African patientsCell, 1986
- Engineering glycoproteins for use as pharmaceuticalsTrends in Biotechnology, 1985